keyword
MENU ▼
Read by QxMD icon Read
search

Sermorelin

keyword
https://www.readbyqxmd.com/read/26879649/qualitative-identification-of-growth-hormone-releasing-hormones-in-human-plasma-by-means-of-immunoaffinity-purification-and-lc-hrms-ms
#1
Andre Knoop, Andreas Thomas, Eric Fichant, Philippe Delahaut, Wilhelm Schänzer, Mario Thevis
The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). The aim of the present study was to develop a method for the simultaneous detection of four different GHRHs and respective metabolites from human plasma by means of immunoaffinity purification and subsequent nano-ultrahigh performance liquid chromatography-high resolution/high accuracy (tandem) mass spectrometry. The target analytes included Geref (Sermorelin), CJC-1293, CJC-1295, and Egrifta (Tesamorelin) as well as two metabolites of Geref and CJC-1293, which were captured from plasma samples using a polyclonal GHRH antibody in concert with protein A/G monolithic MSIA™ D...
May 2016: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/26456392/operation-resistance-a-snapshot-of-falsified-antibiotics-and-biopharmaceutical-injectables-in-europe
#2
Bastiaan J Venhuis, Peter H J Keizers, Rüdiger Klausmann, Ingrid Hegger
Operation Pangea is an annual international week of action combating pharmaceutical crime. In this study, called Operation Resistance, we asked the national agencies in Europe to search for falsified antibiotics and biopharmaceutical injectables (peptides and proteins) amongst the medicines seized in Pangea 7 (2014). Reports were received from Belgium, Cyprus, Czech Republic, Denmark, France, the Netherlands, Portugal, Sweden, Spain, the United Kingdom, Norway, and Switzerland. The countries reported seizing about 21,000 dose units (e...
March 2016: Drug Testing and Analysis
https://www.readbyqxmd.com/read/26382721/expanded-test-method-for-peptides-2-kda-employing-immunoaffinity-purification-and-lc-hrms-ms
#3
Andreas Thomas, Katja Walpurgis, Laura Tretzel, Paul Brinkkötter, Eric Fichant, Philippe Delahaut, Wilhelm Schänzer, Mario Thevis
Bioactive peptides with an approximate molecular mass of 2-12 kDa are of considerable relevance in sports drug testing. Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin), synthetic/animal insulins (lispro, aspart, glulisine, glargine, detemir, degludec, bovine and porcine insulin), synthetic ACTH (synacthen), synthetic IGF-I (longR(3) -IGF-I) and mechano growth factors (human MGF, modified human MGF, 'full-length' MGF)...
November 2015: Drug Testing and Analysis
https://www.readbyqxmd.com/read/23280565/mechanisms-of-synergism-between-antagonists-of-growth-hormone-releasing-hormone-and-antagonists-of-luteinizing-hormone-releasing-hormone-in-shrinking-experimental-benign-prostatic-hyperplasia
#4
Ferenc G Rick, Andrew V Schally, Norman L Block, Andrew Abi-Chaker, Awtar Krishan, Luca Szalontay
BACKGROUND: Benign prostatic hyperplasia (BPH) affects aging men. Combined therapy with antagonists of growth hormone-releasing hormone (GHRH) and of luteinizing hormone-releasing hormone (LHRH or GnRH) induces prostate shrinkage in rat models. We investigated the mechanisms of action of this combination on cell cycle traverse and expression of prostatic genes. METHODS: Effects of GHRH antagonist, JMR-132 (40 µg/day), the LHRH antagonist, cetrorelix (0.625 mg/kg), and their combination were evaluated on testosterone-induced benign prostatic hyperplasia in male Wistar rats...
June 2013: Prostate
https://www.readbyqxmd.com/read/23267837/anti-tumor-effects-of-peptide-analogs-targeting-neuropeptide-hormone-receptors-on-mouse-pheochromocytoma-cells
#5
C G Ziegler, M Ullrich, A V Schally, R Bergmann, J Pietzsch, L Gebauer, K Gondek, N Qin, K Pacak, M Ehrhart-Bornstein, G Eisenhofer, S R Bornstein
Pheochromocytoma is a rare but potentially lethal chromaffin cell tumor with currently no effective treatment. Peptide hormone receptors are frequently overexpressed on endocrine tumor cells and can be specifically targeted by various anti-tumor peptide analogs. The present study carried out on mouse pheochromocytoma cells (MPCs) and a more aggressive mouse tumor tissue-derived (MTT) cell line revealed that these cells are characterized by pronounced expression of the somatostatin receptor 2 (sst2), growth hormone-releasing hormone (GHRH) receptor and the luteinizing hormone-releasing hormone (LHRH) receptor...
May 22, 2013: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/23095641/ghrh-antagonist-when-combined-with-cytotoxic-agents-induces-s-phase-arrest-and-additive-growth-inhibition-of-human-colon-cancer
#6
Ferenc G Rick, Stephan Seitz, Andrew V Schally, Luca Szalontay, Awtar Krishan, Christian Datz, Andreas Stadlmayr, Stefan Buchholz, Norman L Block, Florian Hohla
Treatment of colon cancer with an antagonist of growth hormone-releasing hormone (GHRH), JMR-132, results in a cell cycle arrest in S-phase of the tumor cells. Thus, we investigated the effect of JMR-132 in combination with S-phase-specific cytotoxic agents, 5-FU, irinotecan and cisplatin on the in vitro and in vivo growth of HT-29, HCT-116 and HCT-15 human colon cancer cell lines. In vitro, every compound inhibited proliferation of HCT-116 cells in a dose-dependent manner. Treatment with JMR-132 (5 μM) combined with 5-FU (1...
November 15, 2012: Cell Cycle
https://www.readbyqxmd.com/read/22971474/new-agonist-and-antagonist-based-treatment-approaches-for-advanced-prostate-cancer
#7
REVIEW
Y Xu, Y F Jiang, B Wu
Increased understanding of prostate cancer biology has led to new treatment strategies and promising new agents for treating prostate cancer, in particular peptide-based agonists and antagonists. In this review article, new therapy modalities and potential approaches for the treatment of advanced prostate cancer are discussed, including agonists and antagonists of luteinizing hormone-releasing hormone, antagonists of bombesin/gastrin-releasing peptide, and growth hormone-releasing hormone and somatostatin analogues...
2012: Journal of International Medical Research
https://www.readbyqxmd.com/read/22941871/antagonists-of-growth-hormone-releasing-hormone-suppress-in-vivo-tumor-growth-and-gene-expression-in-triple-negative-breast-cancers
#8
Roberto Perez, Andrew V Schally, Irving Vidaurre, Ricardo Rincon, Norman L Block, Ferenc G Rick
This study evaluated the effects of a modern antagonistic analog of GHRH on tumor growth and on expression of inflammatory cytokine genes in two models of human triple negative breast cancers (TNBC). The TNBC subtype is refractory to the treatment options available for other hormone-independent breast cancers. Inflammatory cytokines play a major role in the cellular signaling associated with breast cancer pathogenesis and enhance epithelial-mesenchymal transitions (EMT), drug resistance, and metastatic potential...
September 2012: Oncotarget
https://www.readbyqxmd.com/read/22777643/inhibitory-effects-of-antagonists-of-growth-hormone-releasing-hormone-on-growth-and-invasiveness-of-pc3-human-prostate-cancer
#9
Laura Muñoz-Moreno, M Isabel Arenas, Andrew V Schally, Ana B Fernández-Martínez, Elías Zarka, Marta González-Santander, María J Carmena, Eva Vacas, Juan C Prieto, Ana M Bajo
New approaches are needed to the therapy of advanced prostate cancer. This study determined the effect of growth hormone-releasing hormone (GHRH) antagonists, JMR-132 and JV-1-38 on growth of PC3 tumors as well as on angiogenesis and metastasis through the evaluation of various factors that contribute largely to the progression of prostate cancer. Human PC3 androgen-independent prostate cancer cells were injected subcutaneously into nude mice. The treatment with JMR-132 (10 μg/day) or JV-1-38 (20 μg/day) lasted 41 days...
February 15, 2013: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/22640814/involvement-of-neurotransmitters-in-the-action-of-growth-hormone-releasing-hormone-antagonist-on-passive-avoidance-learning
#10
Gyula Telegdy, Andrew V Schally
The antagonist MZ-4-71 of growth hormone-releasing hormone (GH-RH) has been shown to suppress the secretion of GH and insulin-like growth factor-1 (IGF-1), suggesting that this class of analogs could be used for the therapy of disorders characterized by excessive GH secretion. Numerous GH-RH antagonists has been synthetized and shown to suppress the growth of various tumors. MZ-4-71 facilitates the consolidation of passive avoidance learning. Beta-amyloid 25-35 impairs the consolidation of passive avoidance learning and MZ-4-71 fully blocks this impairment...
August 1, 2012: Behavioural Brain Research
https://www.readbyqxmd.com/read/22377963/inhibitory-effects-of-ghrh-antagonists-on-human-gh-secreting-adenoma-tissue
#11
Luca Szalontay, Ronald J Benveniste, Andrew V Schally, Irving Vidaurre, Mehrdad Nadji, Marta Zarandi, Norman L Block, Magdolna Kovacs
Experimental data indicate that antagonists of growth hormone-releasing hormone (GHRH) could be used clinically in disorders characterized by excessive GHRH/growth hormone (GH) secretion, but direct evidence for the effectiveness of GHRH antagonists on human pituitary tissue is still lacking. In this study, we investigated the inhibitory effect of our GHRH antagonists MZ-4-71 and JV-1-36 and the somatostatin (SST) analog RC-160 on superfused pituitary cells obtained from a human GH-secreting adenoma. Using Western blot analysis and immunohistochemistry, we demonstrated profuse expression of the GHRH receptor and its major splice variant SV1 and an increase in the expression of Gsa protein in the adenoma tissue...
2012: Neuroendocrinology
https://www.readbyqxmd.com/read/22341819/combining-growth-hormone-releasing-hormone-antagonist-with-luteinizing-hormone-releasing-hormone-antagonist-greatly-augments-benign-prostatic-hyperplasia-shrinkage
#12
Ferenc G Rick, Luca Szalontay, Andrew V Schally, Norman L Block, Mehrdad Nadji, Karoly Szepeshazi, Irving Vidaurre, Marta Zarandi, Magdolna Kovacs, Zoltan Rekasi
PURPOSE: Benign prostatic hyperplasia often affects aging men. Antagonists of the neuropeptide growth hormone-releasing hormone reduced prostate weight in an androgen induced benign prostatic hyperplasia model in rats. Luteinizing hormone-releasing hormone antagonists also produce marked, protracted improvement in lower urinary tract symptoms, reduced prostate volume and an increased urinary peak flow rate in men with benign prostatic hyperplasia. We investigated the influence of a combination of antagonists of growth hormone-releasing hormone and luteinizing hormone-releasing hormone on animal models of benign prostatic hyperplasia...
April 2012: Journal of Urology
https://www.readbyqxmd.com/read/22307626/antagonists-of-growth-hormone-releasing-hormone-inhibit-growth-of-androgen-independent-prostate-cancer-through-inactivation-of-erk-and-akt-kinases
#13
Ferenc G Rick, Andrew V Schally, Luca Szalontay, Norman L Block, Karoly Szepeshazi, Mehrdad Nadji, Marta Zarandi, Florian Hohla, Stefan Buchholz, Stephan Seitz
The management of castration-resistant prostate cancer (CRPC) presents a clinical challenge because of limitations in efficacy of current therapies. Novel therapeutic strategies for the treatment of CRPC are needed. Antagonists of hypothalamic growth hormone-releasing hormone (GHRH) inhibit growth of various malignancies, including androgen-dependent and independent prostate cancer, by suppressing diverse tumoral growth factors, especially GHRH itself, which acts as a potent autocrine/paracrine growth factor in many tumors...
January 31, 2012: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/22203988/activation-of-growth-hormone-releasing-hormone-ghrh-receptor-stimulates-cardiac-reverse-remodeling-after-myocardial-infarction-mi
#14
Rosemeire M Kanashiro-Takeuchi, Lauro M Takeuchi, Ferenc G Rick, Raul Dulce, Adriana V Treuer, Victoria Florea, Claudia O Rodrigues, Ellena C Paulino, Konstantinos E Hatzistergos, Sarah M Selem, Daniel R Gonzalez, Norman L Block, Andrew V Schally, Joshua M Hare
Both cardiac myocytes and cardiac stem cells (CSCs) express the receptor of growth hormone releasing hormone (GHRH), activation of which improves injury responses after myocardial infarction (MI). Here we show that a GHRH-agonist (GHRH-A; JI-38) reverses ventricular remodeling and enhances functional recovery in the setting of chronic MI. This response is mediated entirely by activation of GHRH receptor (GHRHR), as demonstrated by the use of a highly selective GHRH antagonist (MIA-602). One month after MI, animals were randomly assigned to receive: placebo, GHRH-A (JI-38), rat recombinant GH, MIA-602, or a combination of GHRH-A and MIA-602, for a 4-wk period...
January 10, 2012: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/22197299/neurotransmission-of-the-antidepressant-like-effects-of-the-growth-hormone-releasing-hormone-antagonist-mz-4-71
#15
M Tanaka, A V Schally, G Telegdy
MZ-4-71 is an antagonist of growth hormone-releasing hormone (GH-RH) which suppresses the secretion of GH-RH. It has been shown that MZ-4-71 has antidepressive-like effects in a modified forced swimming test (FST) in mice, exerts anxiolytic effects in an elevated plus maze test, improves memory consolidation in passive avoidance learning, and corrects the impairment of memory consolidation caused by β-amyloid 25-35 in mice. However, little is known about the mechanisms of action of MZ-4-71 on brain functions...
March 17, 2012: Behavioural Brain Research
https://www.readbyqxmd.com/read/22041656/ghrh-antagonist-mz-5-156-increases-the-expression-of-ampk-in-a549-lung-cancer-cells
#16
Agnieszka Siejka, Nektarios Barabutis, Andrew V Schally
AMP-activated protein kinase (AMPK) regulates cellular proliferation, growth and metabolism. Targeted activation of AMPK is considered an important therapeutic strategy for cancer treatment. To evaluate the effect of growth hormone-releasing hormone (GHRH) and its antagonist MZ-5-156 on the phosphorylation of AMPK and other related regulatory intracellular proteins we employed human non-small cell lung cancer cell line A549, which expresses GHRH receptors. Treatment of A549 cells with GHRH antagonist decreased cell proliferation and activated AMPK as well as glycogen synthase kinase (GSK)3β...
November 1, 2011: Cell Cycle
https://www.readbyqxmd.com/read/22009378/growth-hormone-releasing-hormone-antagonists-inhibit-growth-of-human-ovarian-cancer
#17
A Papadia, A V Schally, G Halmos, J L Varga, S Seitz, S Buchholz, F Rick, M Zarandi, S Bellyei, A Treszl, L Szalontay, J A Lucci
Epithelial ovarian carcinoma is the leading cause of cancer-related deaths among women with gynecologic malignancies. Antagonists of the growth hormone-releasing hormone (GHRH) have been shown to inhibit growth of various cancers through endocrine, autocrine, and paracrine mechanisms. In this study, we have investigated the effects of GHRH antagonists (GHRHa) in ES-2 human clear cell ovarian cancer and in UCI-107 human serous ovarian cancer in vitro and in vivo. We evaluated the expression of mRNA for GHRH receptor, the binding to GHRH receptors, in specimens of ES-2 ovarian cancer...
October 2011: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://www.readbyqxmd.com/read/21796649/inhibitory-effects-of-antagonists-of-growth-hormone-releasing-hormone-on-experimental-prostate-cancers-are-associated-with-upregulation-of-wild-type-p53-and-decrease-in-p21-and-mutant-p53-proteins
#18
Anton Stangelberger, Andrew V Schally, Ferenc G Rick, Jozsef L Varga, Benjamin Baker, Marta Zarandi, Gabor Halmos
BACKGROUND: The tumor suppressor gene p53 is implicated in cell cycle control and apoptosis. Antagonists of growth hormone-releasing hormone (GHRH) have been shown to inhibit human experimental prostate cancers. METHODS: We investigated the involvement of p53 apoptotic pathways in this effect. Nude mice bearing xenografted PC-3, DU-145, and MDA-PCa-2b human prostate cancer lines were treated with a new potent GHRH antagonist MZ-J-7-138. To determine whether tumor inhibition by MZ-J-7-138 involves apoptotic mechanisms such as p53 and p21, we evaluated by Western Blot the expression of mutant mt-p53 in PC-3 and DU-145 and of wild type (wt-p53) in MDA-PCa-2b prostate cancers as well as p21...
April 2012: Prostate
https://www.readbyqxmd.com/read/21751186/novel-antagonists-of-growth-hormone-releasing-hormone-inhibit-growth-and-vascularization-of-human-experimental-ovarian-cancers
#19
Anna Klukovits, Andrew V Schally, Luca Szalontay, Irving Vidaurre, Andrea Papadia, Marta Zarandi, Jozsef L Varga, Norman L Block, Gabor Halmos
BACKGROUND: Antagonists of growth hormone-releasing hormone (GHRH) inhibit the proliferation of various human cancer cell lines and experimental tumors by mechanisms that include direct action on GHRH receptors in cancer cells. METHODS: In this study, the effects of newly synthesized GHRH antagonists, MIA-313, MIA-602, MIA-604, and MIA-610, were investigated in 2 human ovarian epithelial adenocarcinoma cell lines, OVCAR-3 and SKOV-3, in vitro and in vivo. The expression of receptors for GHRH was demonstrated by Western blot analysis and ligand competition methods in the OVCAR-3 and SKOV-3 cell lines and in tumors from those cells grown in athymic nude mice...
February 1, 2012: Cancer
https://www.readbyqxmd.com/read/21701777/the-effect-of-a-novel-antagonist-of-growth-hormone-releasing-hormone-on-cell-proliferation-and-on-the-key-cell-signaling-pathways-in-nine-different-breast-cancer-cell-lines
#20
Eva Pozsgai, Andrew V Schally, Eniko Hocsak, Marta Zarandi, Ferenc Rick, Szabolcs Bellyei
Growth hormone releasing hormone (GHRH) antagonists have been developed for the treatment of various cancers. We investigated the effects of a novel GHRH antagonist, MIA-602, on nine breast cancer cell lines, differing in their expression for estrogen-, progesterone- and HER-2 receptors. We detected the presence of pituitary-type GHRH receptors (pGHRH-R) on 6 of the 9 breast cancer cell lines. The main splice variant of pGHRH-R, SV1, was found on all 9 cell lines. MTT assay showed that following treatment with MIA-602, cell viability decreased significantly in all 9 cell lines...
October 2011: International Journal of Oncology
keyword
keyword
40184
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"